Bortezomib-related neuropathy may mask CNS relapse in multiple myeloma: A call for diligence

References

• Palumbo A, Anderson KC. Multiple myeloma. N Engl J Med 2011; 364:1046-60; PMID:21410373; http://dx.doi.org/10.1056/NEJMra1011442
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: World Health Organization 2008; 200-13.
   Google Scholar
• Altekruse SF, Kosary CL, Krapcho M, et al. SEER cancer statistics review, 1975–2007. Bethesda, MD: National Cancer Institute.
   Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111(5):2516-20; PMID:17975015; http://dx.doi.org/10.1182/blood-2007-10-116129
   PubMed Web of Science ®Google Scholar
• Abdallah AO, Atrash S, Shahid Z, Jameel M, Grazziutti M, Apewokin S, Kumar NS, Restrepo A, Waheed S, Van Rhee F, et al. Patterns of central nervous system involvement in relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 2014; 14(3):211-4; PMID:24373936; http://dx.doi.org/10.1016/j.clml.2013.11.004
   PubMed Web of Science ®Google Scholar
• Chen CI, Masih-Khan E, Jiang H, Rabea A, Cserti-Gazdewich C, Jimenez-Zepeda VH, Chu CM, Kukreti V, Trudel S, Tiedemann R, et al. Central nervous system involvement with multiple myeloma: Long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents. Br J Haematol 2013; 162:483-8; PMID:23772701; http://dx.doi.org/10.1111/bjh.12414
   PubMed Web of Science ®Google Scholar
• Petersen S, Wagner A, Gimsing P. Cerebral and meningeal multiple myeloma after autologous stem cell transplantation. A case report and review of the literature. Am. J. Hematol 1999; 62:228-33; PMID:10589078; http://dx.doi.org/10.1002/(SICI)1096-8652(199912)62:4%3c228::AID-AJH5%3e3.0.CO;2-3
   PubMed Web of Science ®Google Scholar
• Veinstein A, Brizard A, Randriamalala E, Babin P, Preud'homme JL, Guilhot F. Central nervous system relapses after autologous stem cell transplantation for myeloma. Report of two cases. Hematol. Cell Ther 1997; 39:327-30; PMID:9497892; http://dx.doi.org/10.1007/s00282-997-0327-6
   PubMedGoogle Scholar
• Ria R, Reale A, Vacca A. Novel agents and new therapeutic approaches for treatment of multiple myeloma. World J Methodol 2014; 4(2):73-90; PMID:25332907; http://dx.doi.org/10.5662/wjm.v4.i2.73
   PubMedGoogle Scholar
• Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008; 111: 2521-26; PMID:17901246; http://dx.doi.org/10.1182/blood-2007-08-104984
   PubMed Web of Science ®Google Scholar
• Richardson PG, Delforge M, Beksac M, Wen P, Jongen JL, Sezer O, Terpos E, Munshi N, Palumbo A, Rajkumar SV, et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 2012; 26(4):595-608; PMID:22193964; http://dx.doi.org/10.1038/leu.2011.346
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Jakubowiak AJ. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk Lymphoma 2010; 51(7):1178-87; PMID:20497001; http://dx.doi.org/10.3109/10428194.2010.483303
   PubMed Web of Science ®Google Scholar
• Corso A, Mangiacavalli S, Varettoni M, Pascutto C, Zappasodi P, Lazzarino M. Bortezomib-induced peripheral neuropathy in multiple myeloma: A comparison between previously treated and untreated patients. Leuk Res 2010; 34(4):471-4; PMID:19674790; http://dx.doi.org/10.1016/j.leukres.2009.07.022
   PubMed Web of Science ®Google Scholar
• Fassas AB, Ward S, Muwalla F, Van Hemert R, Schluterman K, Harik S, Tricot G. Myeloma of the central nervous system: strong association with unfavourable chromosomal abnormalities and other high-risk disease features. Leuk Lymphoma 2004; 45:291-300; PMID:15101714; http://dx.doi.org/10.1080/10428190310001597964
   PubMed Web of Science ®Google Scholar
• Alsobhi ES, Hashim IA, Abdelaai MA, Aljifri AM, Alshamy AM. Elevated cerebrospinal fluid B2 microglobulin as a tumor marker in a patient with multiple myeloma of the central nervous system. Saudi Med J 2007; 28:128-30; PMID:17206305
   PubMed Web of Science ®Google Scholar
• Fassas A, Muwalla F, Berryman T, Benramdane R, Joseph L, Anaissie E, Sethi R, Desikan R, Siegel D, Badros A, et al. Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. Br J Haematol 2002; 117:103-8; PMID:11918539; http://dx.doi.org/10.1046/j.1365-2141.2002.03401.x
   PubMed Web of Science ®Google Scholar
• Nazanin M, Wei X, Demopoulos A, Hormigo A, Chari A. Characterization of central nervous system multiple myeloma in the era of novel therapies. Leuk Lymphoma 2016; 4:1-5; PMID:26727654
   PubMed Web of Science ®Google Scholar
• Katodritou E, Terpos E, Kastritis E, Delimpasis S, Symeonidis AS, Repousis P, Kyrtsonis MC, Vadikolia C, Michalis E, Polychronidou G, et al. Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience. Ann Hematol 2015; 94:2033-42; PMID:26420061; http://dx.doi.org/10.1007/s00277-015-2484-y
   PubMed Web of Science ®Google Scholar
• Nieuwenhuizen L, Biesma DH. Central nervous system myelomatosis: review of the literature. Eur J Haematol 2007; 80:1-9; PMID:17961180
   PubMed Web of Science ®Google Scholar
• Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R, Kumar S, Usmani S, Roodman D, Niesvizky R, et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 2014; 28(3):525-42; PMID:24253022; http://dx.doi.org/10.1038/leu.2013.350
   PubMed Web of Science ®Google Scholar
• Mussetti A, Dalto S, Montefusco V. Effective treatment of pomalidomide in central nervous system myelomatosis. Leuk Lymphoma 2013; 54:864-6; PMID:22880953; http://dx.doi.org/10.3109/10428194.2012.718343
   PubMed Web of Science ®Google Scholar
• Potts BC, Albitar MX, Anderson KC, Baritaki S, Berkers C, Bonavida B, Chandra J, Chauhan D, Cusack JC Jr, Fenical W, et al. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets 2011; 11: 254-84; PMID:21247382; http://dx.doi.org/10.2174/156800911794519716
   PubMed Web of Science ®Google Scholar
• Short KD, Rajkumar SV, Larson D, Buadi F, Hayman S, Dispenzieri A, Gertz M, Kumar S, Mikhael J, Roy V, et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia 2011; 25: 906-08; PMID:21350560; http://dx.doi.org/10.1038/leu.2011.29
   PubMed Web of Science ®Google Scholar
• Li Z, Qiu Y, Personett D, Huang P, Edenfield B, Katz J, Babusis D, Tang Y, Shirely MA, Moghaddam MF, et al. Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models. PLoS One 2013; 8(8):e71754; PMID:23940785; http://dx.doi.org/10.1371/journal.pone.0071754
   PubMed Web of Science ®Google Scholar
• Paludo J, Painuly U, Kumar S, Buadi FK, Hayman SR, Lacy MQ, Dispenzieri A, Lust JA, Dingli D, McCurdy A, et al. Myelomatous involvement of the central nervous system: Mayo Clinic experience. ASH Annual Meeting Abstracts 2013, 122: abstr. 3119.
   Google Scholar
• Gangatharan SA, Carney DA, Prince HM, Wolf MM, Januszewicz EH, Ritchie DS, Harrison SJ. Emergence of central nervous system myeloma in the era of novel agents. Hematol Oncol 2012; 30(4):170-4; PMID:22144117; http://dx.doi.org/10.1002/hon.1021
   PubMed Web of Science ®Google Scholar
• Lee D, Kalff A, Low M, Gangatharan S, Ho P, Bajel A, Ritchie D, Grigg A, Spencer A. Central nervous system multiple myeloma–potential roles for intrathecal therapy and measurement of cerebrospinal fluid light chains. Br J Haematol 2013; 162(3): 371-5; PMID:23718539; http://dx.doi.org/10.1111/bjh.12404
   PubMed Web of Science ®Google Scholar